Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94


Safety and efficacy of intensity-modulated stereotactic body radiotherapy using helical tomotherapy for lung cancer and lung metastasis.

Nagai A, Shibamoto Y, Yoshida M, Inoda K, Kikuchi Y.

Biomed Res Int. 2014;2014:473173. doi: 10.1155/2014/473173. Epub 2014 Jun 4.


Outcome and toxicity of stereotactic body radiotherapy with helical tomotherapy for inoperable lung tumor: analysis of Grade 5 radiation pneumonitis.

Aibe N, Yamazaki H, Nakamura S, Tsubokura T, Kobayashi K, Kodani N, Nishimura T, Okabe H, Yamada K.

J Radiat Res. 2014 May;55(3):575-82. doi: 10.1093/jrr/rrt146. Epub 2014 Jan 23.


Comparison of Effects Between Central and Peripheral Stage I Lung Cancer Using Image-Guided Stereotactic Body Radiotherapy via Helical Tomotherapy.

He J, Huang Y, Shi S, Hu Y, Zeng Z.

Technol Cancer Res Treat. 2015 Dec;14(6):701-7. doi: 10.1177/1533034615583206. Epub 2015 Apr 24.


Stereotactic body radiotherapy for central lung tumors.

Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH.

J Thorac Oncol. 2012 Sep;7(9):1394-9. doi: 10.1097/JTO.0b013e3182614bf3.


Analysis of dose distribution and risk of pneumonitis in stereotactic body radiation therapy for centrally located lung tumors: a comparison of robotic radiosurgery, helical tomotherapy and volumetric modulated arc therapy.

Kannarunimit D, Descovich M, Garcia A, Chen J, Weinberg V, Mcguinness C, Pinnaduwage D, Murnane J, Gottschalk AR, Yom SS.

Technol Cancer Res Treat. 2015 Feb;14(1):49-60. doi: 10.7785/tcrt.2012.500394. Epub 2014 Nov 11.


Dose as a function of lung volume and planned treatment volume in helical tomotherapy intensity-modulated radiation therapy-based stereotactic body radiation therapy for small lung tumors.

Baisden JM, Romney DA, Reish AG, Cai J, Sheng K, Jones DR, Benedict SH, Read PW, Larner JM.

Int J Radiat Oncol Biol Phys. 2007 Jul 15;68(4):1229-37. Epub 2007 May 21.


Toxicity and outcome results of a class solution with moderately hypofractionated radiotherapy in inoperable Stage III non-small cell lung cancer using helical tomotherapy.

Bral S, Duchateau M, Versmessen H, Engels B, Tournel K, Vinh-Hung V, De Ridder M, Schallier D, Storme G.

Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1352-9. doi: 10.1016/j.ijrobp.2009.06.075. Epub 2010 Jan 7.


Feasibility report of image guided stereotactic body radiotherapy (IG-SBRT) with tomotherapy for early stage medically inoperable lung cancer using extreme hypofractionation.

Hodge W, Tomé WA, Jaradat HA, Orton NP, Khuntia D, Traynor A, Weigel T, Mehta MP.

Acta Oncol. 2006;45(7):890-6.


Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy.

Modh A, Rimner A, Williams E, Foster A, Shah M, Shi W, Zhang Z, Gelblum DY, Rosenzweig KE, Yorke ED, Jackson A, Wu AJ.

Int J Radiat Oncol Biol Phys. 2014 Dec 1;90(5):1168-76. doi: 10.1016/j.ijrobp.2014.08.008. Epub 2014 Oct 8.


Treatment of single or multiple brain metastases by hypofractionated stereotactic radiotherapy using helical tomotherapy.

Nagai A, Shibamoto Y, Yoshida M, Wakamatsu K, Kikuchi Y.

Int J Mol Sci. 2014 Apr 22;15(4):6910-24. doi: 10.3390/ijms15046910.


Outcomes of stereotactic body radiotherapy (SBRT) treatment of multiple synchronous and recurrent lung nodules.

Owen D, Olivier KR, Mayo CS, Miller RC, Nelson K, Bauer H, Brown PD, Park SS, Ma DJ, Garces YI.

Radiat Oncol. 2015 Feb 18;10:43. doi: 10.1186/s13014-015-0340-9.


Dose escalated, hypofractionated radiotherapy using helical tomotherapy for inoperable non-small cell lung cancer: preliminary results of a risk-stratified phase I dose escalation study.

Adkison JB, Khuntia D, Bentzen SM, Cannon GM, Tome WA, Jaradat H, Walker W, Traynor AM, Weigel T, Mehta MP.

Technol Cancer Res Treat. 2008 Dec;7(6):441-7.


Clinical outcome of stereotactic body radiotherapy for primary and oligometastatic lung tumors: a single institutional study with almost uniform dose with different five treatment schedules.

Aoki M, Hatayama Y, Kawaguchi H, Hirose K, Sato M, Akimoto H, Fujioka I, Ono S, Tsushima E, Takai Y.

Radiat Oncol. 2016 Jan 20;11:5. doi: 10.1186/s13014-016-0581-2.


Ablative or palliative stereotactic body radiotherapy with helical tomotherapy for primary or metastatic lung tumor.

Marcenaro M, Vagge S, Belgioia L, Agnese D, Lamanna G, Mantero E, Gusinu M, Garelli S, Cavagnetto F, Agostinelli S, Corvò R.

Anticancer Res. 2013 Feb;33(2):655-60.


Hypofractionated radiotherapy for primary or secondary oligometastatic lung cancer using Tomotherapy.

Chang HJ, Ko HL, Lee CY, Wu RH, Yeh YW, Jiang JS, Kao SJ, Chi KH.

Radiat Oncol. 2012 Dec 27;7:222. doi: 10.1186/1748-717X-7-222.


Radiobiological impact of dose calculation algorithms on biologically optimized IMRT lung stereotactic body radiation therapy plans.

Liang X, Penagaricano J, Zheng D, Morrill S, Zhang X, Corry P, Griffin RJ, Han EY, Hardee M, Ratanatharathom V.

Radiat Oncol. 2016 Jan 22;11:10. doi: 10.1186/s13014-015-0578-2.


Stereotactic body radiation therapy (SBRT) for lung malignancies: preliminary toxicity results using a flattening filter-free linear accelerator operating at 2400 monitor units per minute.

Prendergast BM, Dobelbower MC, Bonner JA, Popple RA, Baden CJ, Minnich DJ, Cerfolio RJ, Spencer SA, Fiveash JB.

Radiat Oncol. 2013 Nov 20;8:273. doi: 10.1186/1748-717X-8-273.


Analysis of intrafractional organ motion by megavoltage computed tomography in patients with lung cancer treated with image-guided stereotactic body radiotherapy using helical tomotherapy.

Aibe N, Yamazaki H, Nishimura T, Oota Y, Iwama K, Nakamura S, Ikeno H, Yoshida K, Okabe H, Yamada K.

Anticancer Res. 2014 Dec;34(12):7383-8.


Volumetric modulated arc therapy for lung stereotactic radiation therapy can achieve high local control rates.

Yamashita H, Haga A, Takahashi W, Takenaka R, Imae T, Takenaka S, Nakagawa K.

Radiat Oncol. 2014 Nov 11;9:243. doi: 10.1186/s13014-014-0243-1.

Supplemental Content

Support Center